It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...
Shareholders are advised that on Wednesday, 4 March 2026, it was announced that the Lighthouse board of directors (the ‘Board’) has approved a final dividend of 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results